Wild type and mutant combine

McCarthy, Nicola

doi:10.1038/nrc3224

In Brief
Published: 24 January 2012

Signalling

Wild type and mutant combine

Nicola McCarthy

Nature Reviews Cancer volume 12, page 81 (2012)Cite this article

270 Accesses
Metrics details

Subjects

Access through your institution

Buy or subscribe

This study by Walter Kolch and colleagues indicates that mutant KRAS leads to the stabilization of p53 through the MST2–LATS1 kinase pathway, which results in apoptosis. This is counteracted through mutant KRAS activation of the epidermal growth factor receptor and the remaining wild-type KRAS allele, which inhibits the MST2 pathway through the activation of AKT. Consistently, there is a negative correlation in mouse and human colorectal tumours between mutant KRAS expression and MST2 expression, and tumours that express both have increased levels of apoptosis.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

Purchase on SpringerLink
Instant access to full article PDF

Buy now

Prices may be subject to local taxes which are calculated during checkout

ORIGINAL RESEARCH PAPER

Matallanas, D. et al. Mutant KRAS activation of the proapoptotic MST2 pathway is antagonized by wild-type KRAS. Mol. Cell 44, 893–906 (2011)Article
Article CAS Google Scholar

Download references

Authors